Clinical Trials Logo
  1. Home
  2. Condylomata Acuminata
  3. NCT03158480
  4. Details
NCT03158480 Clinical Trial

Safety and Efficacy of Immune Therapy for Condyloma

Condylomata Acuminata Clinical Trial

Official title:
Safety and Efficacy of Immune Therapy for Condyloma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03158480
Other study ID # 20173357201827
Secondary ID
Status Recruiting
Phase N/A
First received May 16, 2017
Last updated June 28, 2017
Start date June 25, 2017
Est. completion date June 30, 2019

Study information
Verified date March 2017
Source Shenzhen Second People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.

Recruitment information / eligibility
Status Recruiting
Enrollment 80
Est. completion date June 30, 2019
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:All patients have typical clinical characters of condyloma, positive for HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for over half a year without completely recovery. All patients or their family will sign informed consent and approved by Ethics Committee of Shenzhen Second People's Hospital -

Exclusion Criteria:pregnant, blood disease, contraindication for immune therapy, allergic to interferon

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• DC-CIK immunotherapy
Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients

Locations
Country Name City State
China Shenzhen Second Hospital Shenzhen Guangdong

Sponsors (1)
Lead Sponsor Collaborator
Shenzhen Second People's Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Condylomata Acuminata recurrence rate Condylomata Acuminata recurrence rate in 6 months after treatment 6 months
Secondary skin tissue HPV gene use PCR to testify skin tissue HPV gene 6 months
Secondary side effect evaluate and record side effect of each group 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Completed NCT00090285 - An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Phase 3
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02015260 - A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts Phase 2
Active, not recruiting NCT05056402 - An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old Phase 3
Withdrawn NCT00365443 - Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) Phase 2
Not yet recruiting NCT01483794 - Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile N/A
Not yet recruiting NCT06430190 - Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata N/A
Completed NCT03935204 - Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 2
Completed NCT02405520 - Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine Phase 1
Active, not recruiting NCT02710851 - Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine Phase 2
Completed NCT04782895 - Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age Phase 3
Completed NCT03546842 - Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) Phase 3
Completed NCT03981822 - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts Phase 2
Completed NCT01598779 - Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population N/A
Completed NCT00449982 - Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Phase 3
Completed NCT03813940 - Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 1
Not yet recruiting NCT06197802 - Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Completed NCT01532102 - Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts Phase 1/Phase 2
Active, not recruiting NCT06297187 - Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study